UBS has maintained a neutral recommendation for Novo Nordisk A/S, a company focused on the design, manufacture, and marketing of pharmaceutical products. The majority of its sales come from diabetes and obesity treatments (92.6%), with the remainder from rare disease treatments (7.4%). Geographically, sales are distributed as follows: Europe-Middle East-Africa (21.9%), United States (54.9%), North America (3.9%), China (7.2%), and others (12.1%).
